113242-33-4

Basic information

• Product Name: 4-CHLORO-2-(4-FLUORO-PHENYL)-QUINAZOLINE
• Synonyms: 4-CHLORO-2-(4-FLUORO-PHENYL)-QUINAZOLINE;AKOS BBS-00000917
• CAS NO: 113242-33-4
• Molecular Formula: C14H8ClFN2
• Molecular Weight: 258.68
• Mol File: 113242-33-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 297.8±32.0 °C(Predicted)
• Appearance: /
• Density: 1.351±0.06 g/cm3(Predicted)
• PKA: 0.44±0.30(Predicted)
• CAS DataBase Reference: 4-CHLORO-2-(4-FLUORO-PHENYL)-QUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-2-(4-FLUORO-PHENYL)-QUINAZOLINE(113242-33-4)
• EPA Substance Registry System: 4-CHLORO-2-(4-FLUORO-PHENYL)-QUINAZOLINE(113242-33-4)

Safety Data

• Hazardous Substances Data: 113242-33-4(Hazardous Substances Data)

Usage

General Description

4-CHLORO-2-(4-FLUORO-PHENYL)-QUINAZOLINE is a chemical compound that belongs to the quinazoline class of organic compounds. It is characterized by the presence of a quinazoline skeleton, which consists of a benzene ring fused to a pyrimidine ring. The compound also contains a chlorine atom and a 4-fluoro-phenyl group, which are attached to different positions on the quinazoline skeleton. This chemical is of interest in the field of medicinal chemistry, as it has potential applications in drug development due to its ability to modulate biological pathways and target specific disease processes. Its unique structure and properties make it a promising candidate for further research and development in the pharmaceutical industry.

Upstream product

• 403-43-0 4-fluorobenzoyl chloride 
• 118-92-3 anthranilic acid 

Relevant articles and documents

Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance

P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a principal obstacle for successful cancer chemotherapy. A novel P-gp inhibitor with a quinazoline scaffold, 12k, was considered to be the most promising for in-depth study. 12k possessed high potency (EC50 = 57.9 ± 3.5 nM), low cytotoxicity, and long duration of activity in reversing doxorubicin (DOX) resistance in K562/A02 cells. 12k also boosted the potency of other MDR-related cytotoxic agents with different structures, increased accumulation of DOX, blocked P-gp-mediated Rh123 efflux, and suppressed P-gp ATPase activity in K562/A02 MDR cells. However, 12k did not have any effects on CYP3A4 activity or P-gp expression. In particular, 12k had a good half-life and oral bioavailability and displayed no influence on DOX metabolism to obviate the side effects closely related to increased plasma concentrations of cytotoxic agents in vivo.

QUINAZOLINE DERIVATIVES AS INHIBITORS OF P-38 alpha

-